


FORM PTO-1390 (REV. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER P/2432-44	
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 1.5em; font-weight: bold;">10/009709</div>	
INTERNATIONAL APPLICATION NO. PCT/SE00/00930		INTERNATIONAL FILING DATE 11 May 2000		PRIORITY DATE CLAIMED 17 May 1999	
TITLE OF INVENTION <div style="text-align: center;">PREVENTION OF DENTAL CARIES</div>					
APPLICANT(S) FOR DO/EO/US <div style="text-align: center;">Nicklas STROMBERG et al.</div>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). - unsigned 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with 37 CFR 1.96. 18. <input type="checkbox"/> A second copy of the published international application and English language translation of the international application. 19. <input type="checkbox"/> A second copy of the English language translation of the international application. 20. <input checked="" type="checkbox"/> Other items or information: PEFS Print form. 3 sheets of drawings. Sequence Listing with disk.					

**EXPRESS MAIL CERTIFICATE**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee (mail label EL334617104US in an envelope addressed to: Asst. Commissioner for Patents, Washington, D.C. 20231, on November 16, 2001

Dorothy Jenkins  
 Name of Person Mailing Correspondence  
  
 Signature  
November 16, 2001  
 Date of Signature

U.S. APPLICATION NO. <b>10/0097709</b>		INTERNATIONAL APPLICATION NO. PCT/SE00/00930		ATTORNEY'S DOCKET NUMBER P/2432-44	
--	--	---	--	---------------------------------------	--

21. ☒ The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO. .... \$1040.00

International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO ..... \$890.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO  
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$740.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	17 - 20 =	0	x \$18.00	\$
Independent claims	1 - 3 =	0	x \$84.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1040.00

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above  
are reduced by 1/2. + \$

**SUBTOTAL =** \$ 1040.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)). \$

**TOTAL NATIONAL FEE =** \$ 1040.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$

**TOTAL FEES ENCLOSED =** \$ 1040.00

	Amount to be refunded:	\$
	charged:	\$

Amount to be refunded: \$

charged: \$

a. ☒ A check in the amount of \$ 1040. to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 15-0700. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card  
information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Check No. 7364


  

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

OSTROLENK, FABER, GERB & SOFFEN, LLP  
1180 Avenue of the Americas  
New York, NY 10036-8403

Tel: (212) 382 0700

  
SIGNATURE

Edward A. Meilman  
NAME

24,735  
REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Nicklas Strömberg et al.

Date: November 16, 2001

Serial No..

Group Art Unit:

Filed:

Examiner:

For: PREVENTION OF DENTAL CARIES

Asst. Commissioner for Patents

Washington, D.C. 20231

AMENDMENT/SUBMISSION

Prior to examination, please amend the application as follows.

FEE CALCULATION

Any additional fee required has been calculated as follows:

\_\_\_\_\_ If checked, "Small Entity" status is claimed.

	NO. CLAIMS AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		EXTRA PRESENT		RATE	ADDIT. FEE
TOTAL	17	MINUS	20	* =	0	X	(\$9 SE or \$18)	\$
INDEP.	1	MINUS	3	** =	0	X	(\$42 SE or \$84)	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM						X	(\$140 SE or \$280)	\$

\* not less than 20 \*\* not less than 3

TOTAL \$ -0-

If any additional payment is required, a check which includes the calculated fee of \$ \_\_\_\_\_  
(OFGS Check No. \_\_\_\_\_) is attached.

In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

**CONTINGENT EXTENSION REQUEST**

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. §1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. §1 135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

**AMENDMENTS**

  X   If checked, amendment(s) to the specification and/or claims are submitted herewith.

**Claims:**

Please amend claims 5, 6 and 8 and add new claims 9-17 pursuant to 37 C.F.R. § 1.121(c)(i) as set forth in the "clean" version attached hereto as Appendix A. Entry is respectfully requested. A version with markings to show the changes made pursuant to 37 C.F.R. § 1.121(c)(ii) is attached hereto as Appendix B.

**REMARKS/ARGUMENT**

This Preliminary Amendment is being submitted to change the multiple dependent claims to single dependent claims in order to eliminate the improper multiple dependent claims and to reduce the government filing fee.

**EXPRESS MAIL CERTIFICATE**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail to Addressee (mail label # EL534617104US) in an envelope addressed to: Asst. Commissioner for Patents, Washington, D.C. 20231, on November 16, 2001

Dorothy Jenkins


Name of Person Mailing Correspondence

  
Signature

November 16, 2001

Date of Signature

Respectfully submitted,



Edward A. Meilman

Registration No.: 24,735

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone: (212) 382-0700

**APPENDIX A**  
**“CLEAN” VERSION OF EACH PARAGRAPH/SECTION/CLAIM**  
**37 C.F.R. § 1.121(b)(ii) AND (c)(i)**

**CLAIMS (with indication of amended or new):**

5. (Amended) A method of preventing dental caries comprising the oral administration of a prevention-effective amount of the peptide of claim 1.

6. (Amended) A composition for preventing dental caries comprising a prevention-effective amount of the oligopeptide of claim 1.

8. (Amended) The manufacture of a medicament for prevention of dental caries comprising a prevention-effective amount of the oligopeptide of claim 1.

9. (NEW) A method of preventing dental caries comprising the oral administration of a prevention-effective amount of the peptide of claim 2.

10 (NEW) A method of preventing dental caries comprising the oral administration of a prevention-effective amount of the peptide of claim 3.

11. (NEW) A method of preventing dental caries comprising the oral administration of a prevention-effective amount of the peptide of claim 4.

12. (NEW) A composition for preventing dental caries comprising a prevention-effective amount of the oligopeptide of claim 2.

13 (NEW) A composition for preventing dental caries comprising a prevention-effective amount of the oligopeptide of claim 3.

14. (NEW) A composition for preventing dental caries comprising a prevention-effective amount of the oligopeptide of claim 4.

15. (NEW) The manufacture of a medicament for prevention of dental caries comprising a prevention-effective amount of the oligopeptide of claim 2.

16. (NEW) The manufacture of a medicament for prevention of dental caries comprising a prevention-effective amount of the oligopeptide of claim 3.

17. (NEW) The manufacture of a medicament for prevention of dental caries comprising a prevention-effective amount of the oligopeptide of claim 4.

**APPENDIX B****VERSION WITH MARKINGS TO SHOW CHANGES MADE****37 C.F.R. § 1.121(b)(iii) AND (c)(ii)****CLAIMS:**

5. (Amended) A method of preventing dental caries comprising the oral administration of a prevention-effective amount of the peptide of [any of claims] claim 1[-4].

6. (Amended) A composition for preventing dental caries comprising a prevention-effective amount of the oligopeptide of [any of claims] claim 1[-4].

8. (Amended) The manufacture of a medicament for prevention of dental caries comprising a prevention-effective amount of the oligopeptide of [any of claims] claim 1[-4].

100091040097092

531 Rec'd PCT/AT 19 NOV 2001

P/2432-44

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

Nicklas Strömberg et al.

Serial No.: Not Yet Known

Filed: Herewith

For: PREVENTION OF DENTAL CARIES

Date: November 16, 2001

Group Art Unit: --

Examiner: --

-----  
Assistant Commissioner for Patents

Box Patent Application

Washington, D.C. 20231


**STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)**

Sir:

Pursuant to 37 C.F.R. §1.821(f), I hereby certify that the contents of the sequence listings enclosed in the above-identified patent application papers and the contents of the computer readable form of the sequence listings are the same.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Charles C. Achkar

Registration No.: 43,311

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone: (212) 382-0700

3/PRTS

1

10009709-062002-44  
p/2432-44

**PREVENTION OF DENTAL CARIES**

10/009709

531 Rec'd PCT/PT 19 NOV 2001

**FIELD OF THE INVENTION**

- 5 The present invention relates to a means for preventing dental caries, a corresponding method, and compositions incorporating the means.

**BACKGROUND OF THE INVENTION**

10

Proline-rich proteins (PRPs) comprise about 70% of the proteins in saliva. They can be divided into acidic, basic, and glycosylated PRPs encoded by six clustered genes on chromosome 12p13.2. PRPs are potential determinants of host susceptibility to dental caries. Large multifunctional 150-residue PRPs (Lamkin M S and Oppenheim F G, Crit Rev Oral Biol Rev 4 (1993) 251-9) are known to adsorb to hydroxyapatite surfaces and inhibit calcium phosphate precipitation, modulate hydroxyapatite crystal formation as well as mediate adhesion of commensal *Actinomyces* and *Streptococcus* species to tooth surfaces. In addition, they bind to and inactivate ingested plant polyphenols (tannins). The proline-poor N-terminal 30 residue domain confers hydroxyapatite- and calcium-binding, while the proline-rich middle/C-terminal domain binds bacteria via the ProGln-terminus and tannins via proline-rich repeats.

15  
20  
25

The polymorphism of acidic PRPs involves allelic and post-translational variants; several common allelic (large PRP-1, PRP-2, Db-s, PIF-s and Pa) and post-translational (small PRP-3, PRP-4, Db-f and PIF-f) variants have been described. In regard of biological properties the acidic PRP variants differ somewhat, and large and small acidic PRPs largely,

30

{00538006.1}

between each other. The small 106 residue acidic PRPs resulting from proteolytic cleavage at Arg106-Gly107 display poor bacterial adhesion activity but high affinity for hydroxyapatite surfaces. Both large and small acidic PRPs are secreted from the acinus cells. After secretion, the acidic PRPs are rapidly enriched on tooth surfaces and degraded as a consequence of bacterial proteolysis. Also, multiple phosphorylated peptides reminiscent of PRPs have been identified in saliva and found to possess increased affinity for hydroxyapatite surfaces. Some studies (Kousvelari E E et al., J Dent Res 59 (1980) 1430-8), though not others (Mandel I D & Bennick A, J Dent Res 62 (1980) 943-5), have associated this proteolytic activity to gingivitis and rate of plaque formation.

Arg catabolism to ammonia has been suggested to be a characteristic of streptococcal biotypes with tooth protective properties (Andersson C et al. Infect Immun 43 (1984) 555-60; Rogers AH, Aust Dent J 35 (1990) 468-71. Wijeyeweera R L & Kleinberg, Arch Oral Biol 34 (1989) 55-64; ibid. 43-53). Actually, Arg can control the ecological relationship between *S. sanguis* and *S. mutans* (van der Hoeven J S et al., J Dent Res 63 (1984) 389-92. Rogers A H et al., Oral Microbiol Immunol 2 (1987) 172-82), and caries-susceptible and caries-resistant subjects differ in ability to raise pH after an acidification (Abelson D C & Mandel I D, J Dent Res 60 (1981) 1634-8; Kleinberg I et al., Proc. "Microbial aspects of dental caries". Sp. Supp. Microbiol. Abstracts. IRL, Washington, D.C., 1976, 433-464 pp).

Arg catabolism is present in *S. sanguis*, *S. gordonii*, *S. anginosus* and *S. mitis*, while it is absent in *S. oralis* and cariogenic *S. mutans* and *S. sobrinus* (Kilian M et al., Int J

Syst Bacteriol 39 (1989) 471-484). Arg-containing peptides, notably sialin (Coulter W A et al., Biochem Soc Trans 18 (1990) 337-8) may act as a local pH-buffering agents by bacterial catabolism of Arg to ammonia via the arginine  
5 deaminase pathway (Floderus E et al., APMIS 98 (1990) 1045-52).

Degradation of acidic PRPs releases oligopeptides which are transported intra-cellularly and metabolized for nutritional  
10 reasons (Kunji E R et al., Antonie Van Leeuwenhoek 70 (1996) 187-221). Gram-negative bacteria colonizing the gingival pocket, such as *Porphyromonas gingivalis*, express a broad range of proteases in utilizing proteins as a major source of energy. In contrast, commensal streptococci and  
15 actinomycetes, which dominate on oral mucosal and tooth surfaces, express multiple glycosidases in utilizing carbohydrates as a major energy source. Nevertheless, protease and peptidase activities, such as a trypsin-like serine endoprotease in *S. oralis*, S-IgA1 proteases in *S.*  
20 *sanguis* and *S. oralis* and yet uncharacterized proteolytic activity, are present in *Streptococcus* and *Actinomyces* species. However, little is known about the degradation of acidic PRPs by these commensal and early colonizing bacteria.

25 While a vast amount of knowledge about saliva constituents and their possible role in processes leading to dental caries has been gathered, that knowledge up to now resulted in only few practically applicable propositions of how to  
30 efficiently prevent dental caries.

#### OBJECTS OF THE INVENTION

{00538006.1}

It is an object of the invention to provide a means for protecting dental surfaces against caries.

It is another object of the invention to provide a  
5 corresponding method.

It is a further object of the invention to provide a composition for protecting dental surfaces against caries.

10 Still other objects of the invention will become apparent from the following description of the invention and preferred embodiments thereof, as well as from the appended claims.

#### 15 DESCRIPTION OF THE INVENTION

The present invention is based on the insight that commensal *Actinomyces* and *Streptococcus* species transform acidic PRPs to small-size peptides, such as pentapeptides. These small-  
20 size peptides are transformed into ammonia by the action of certain oral bacteria. The ammonia thus formed protects raises the pH at the dental surface and thereby protects the surface against caries.

25 In this transformation Arg-containing oligopeptides are released and catabolized to ammonia at or near the dental surface. Ammonia increases the pH at the dental surface and thereby counteracts caries which is promoted by a low pH in the oral cavity.

30

The present invention is also based on the insight that the aforementioned transformation gives rise to peptides with terminal proline or proline-glutamine entities having

affinity to dental surfaces and thus competitively protecting them.

Degradation of acidic PRPs by *Streptococcus* and *Actinomyces* species comprises the following features:

- (i) step-by-step the large 150 residue PRP-1 protein is degraded into intermediate size peptides and finally into smaller oligopeptides and amino acids. Cell-bound endoproteases with broad substrate specificities are involved in the initial stages of this degradation;
- (ii) cleavage of acidic PRPs occurs preferentially in the middle/C-terminal proline-rich 96-140 region; the 106 residue PRP-3 is relatively resistant to cleavage, PRP-3-like peptides being generated by all strains and a series of fragments in region 96-140. Both endoprotease specificity *per se* and intrinsic properties of acidic PRPs, such as the extended structure of proline-rich stretches, explains this regional preference of cleavage;
- (iii) degradation of PRP-1 releases oligopeptides both immediately and after prolonged degradation. The immediate release of an Arg106Gly107Arg108Pro109Gln110 pentapeptide is indicated by the N-terminal 105 residue Pyr1-Pro104Pro105 and the C-terminal 40 residue Gly111-Pro149Gln150 peptides initially generated by *S. gordonii* strain SK12.

Mass spectroscopy identified a N-terminal pyroglutamatic acid (Pyr) post-translational modification of acidic PRPs that blocks sequencing by Edman degradation. The peptide structures derived from degradation of the 150 residue PRP-1 by *S. gordonii* strain SK12 indicate:

- (i) the instant release of an Arg106Gly107Arg108Pro109Gln110 pentapeptide together with a N-terminal 105 residue Pyr1-

Pro104Pro105 and a C-terminal 40 residue Gly111-Pro149Gln150 peptide;

(ii) the generation of multiple middle/C-terminal peptides with ProGln-termini;

- 5 (iii) the cleavage at peptide bonds formed at Pro or Gln residues: Pro95-Pro96, Pro104-Pro105, Pro105-Arg106, Gln110-Gly111, Gln131-Gly132, Pro135-Gln136, Gln136-Gly137, and Gln141-Gly142.

- 10 Degradation of acidic PRPs by *S. gordonii* SK12 initially generates a pentapeptide, Arg106Gly107Arg108Pro109Gln110, containing two of the five Arg residues in PRP-1.

The N-terminal Glu1-Pro104Pro105 peptide derived from PRP-1  
15 by *S. gordonii* SK12 lacks the bacterial adhesion-promoting ProGln-terminus, but contains the hydroxyapatite binding domain. Since small phosphorylated proline-rich peptides and PRP-3 display increased affinity for hydroxyapatite surfaces (Moreno E C et al., J Biol Chem 257 (1982) 2981-9;

- 20 Madapallimattam G & Bennick A, Biochem J 270 (1990) 297-304; Lamkin M S et al., J Dent Res 75 (1996) 803-8), such N-terminal peptides can affect bacterial adhesion by occupying hydroxyapatite sites or altering the pellicle mosaic of binding structures. Proteolytic cleavage is known to unmask  
25 hidden binding structures (Gibbons R J et al., Arch Oral Biol 35 Suppl (1990) 107s-114s), and strains of *Actinomyces* species recognize diverse sites in acidic PRPs and statherin (Hallberg K et al., Oral Microbiol Immunol 13 (1998) 327-336; Li T et al., Infect Immun 67 (1999) 2053-9).

- 30 Furthermore, acidic PRP-degradation generated multiple middle/C-terminal peptides with adhesion-active ProGln-termini, potentially inhibiting the adhesion of oral pathogens binding to acidic PRPs and statherin, i. e. *S.*

*mutans* (Gibbons R J & Hay D I, J Dent Res 68 (1989) 1303-7),  
*P. gingivalis* (Amano A et al., Infect Immun 62 (1994) 3372-80) and *Fusobacterium nucleatum* (Xie H et al., Oral Microbiol Immunol 6 (1991) 257-63). Commensal and pathogenic  
5 species display high and low avidity binding to acidic PRPs, respectively, and may respond differently to ProGln-terminating peptides. Alternatively, both the N-terminal and middle/C-terminal peptides could act as inhibitors or retarders of plaque formation in a broader sense.

10

While the inventors believe these explanations to be true they are of a hypothetical nature and should not be understood so as to limit the scope of the invention which is only determined by the appended claims.

15

According to the invention is disclosed an oligopeptide protecting against dental caries comprising two arginine residues selected from the group consisting of pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide and  
20 decapeptide. Particularly preferred is the pentapeptide ArgGlyArgProGln.

25

Also preferred is a penta- to decapeptide comprised by the sequence of amino acid 99 to amino acid 115 of the 150 residue PRP-1 protein:

GlyGlyHisProArgProProArgGlyArgProGlnGlyProProGlnGln,  
with the proviso that it contains two or more Arg.

Also preferred are the following peptides:

30

ArgGlyArgProGln (residues 106-110);  
ArgGlyArgProGlnGly (residues 106-111);  
ArgGlyArgProGlnGlyPro (residues 106-112);  
ArgGlyArgProGlnGlyProPro (residues 106-113);

{00538006 1}

ArgGlyArgProGlnGlyProProGln (residues 106-114);  
ArgGlyArgProGlnGlyProProGlnGln (residues 106-115);  
GlyGlyHisProArgProProArgGlyArg (residues 99-108);  
GlyHisProArgProProArgGlyArg (residues 100-108);  
5 HisProArgProProArgGlyArg (residues 101-108);  
ProArgProProArgGlyArg (residues 102-108);  
ArgProProArgGlyArg (residues 103-108);  
ProProArgGlyArg (residues 104-108).

10 The peptides of the invention can be easily synthesized by  
solid phase or liquid phase methods known in the art.

According to the invention is disclosed a method of  
preventing dental caries comprising the oral administration  
15 of a prevention-effective amount of an oligopeptide  
comprising two arginine residues selected from the group  
consisting of pentapeptide, hexapeptide, heptapeptide,  
octapeptide, nonapeptide and decapeptide. Particularly  
preferred is the pentapeptide ArgGlyArgProGln for use in the  
20 method of preventing dental caries.

Also preferred for use in the method of preventing dental  
caries is a penta- to decapeptide comprised by the sequence  
of amino acid 99 to amino acid 115 of the 150 residue PRP-1  
25 protein: GlyGlyHisProArgProProArgGlyArgProGlnGlyProProGlnGln,  
with the proviso that it contains two or more Arg.

Also preferred for use of preventing dental caries are the  
following peptides:

30 ArgGlyArgProGln (residues 106-110);  
ArgGlyArgProGlnGly (residues 106-111);  
ArgGlyArgProGlnGlyPro (residues 106-112);  
ArgGlyArgProGlnGlyProPro (residues 106-113);

ArgGlyArgProGlnGlyProProGln (residues 106-114);  
ArgGlyArgProGlnGlyProProGlnGln (residues 106-115);  
GlyGlyHisProArgProProArgGlyArg (residues 99-108);  
GlyHisProArgProProArgGlyArg (residues 100-108);  
5 HisProArgProProArgGlyArg (residues 101-108);  
ProArgProProArgGlyArg (residues 102-108);  
ArgProProArgGlyArg (residues 103-108);  
ProProArgGlyArg (residues 104-108).

- 10 According to the invention is disclosed a composition for preventing dental caries comprising a prevention-effective amount of an oligopeptide comprising two arginine residues selected from the group consisting of pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide and  
15 decapeptide, and a suitable carrier. Particularly preferred is the pentapeptide ArgGlyArgProGln. Suitable carriers include state-of-the-art toothpaste and mouthwash compositions but also chewing-gums, lozenges, and the like.
- 20 Also preferred for use in the composition for preventing dental caries is a penta- to decapeptide comprised by the sequence of amino acid 99 to amino acid 115 of the 150 residue PRP-1 protein:  
GlyGlyHisProArgProProArgGlyArgProGlnGlyProProGlnGln,  
25 with the proviso that it contains two or more Arg.

Also preferred for use in the composition for preventing dental caries are the following peptides:

- ArgGlyArgProGln (residues 106-110);  
30 ArgGlyArgProGlnGly (residues 106-111);  
ArgGlyArgProGlnGlyPro (residues 106-112);  
ArgGlyArgProGlnGlyProPro (residues 106-113);  
ArgGlyArgProGlnGlyProProGln (residues 106-114);  
ArgGlyArgProGlnGlyProProGlnGln (residues 106-115);  
{00538006.1}

GlyGlyHisProArgProProArgGlyArg (residues 99-108);

GlyHisProArgProProArgGlyArg (residues 100-108);

HisProArgProProArgGlyArg (residues 101-108);

ProArgProProArgGlyArg (residues 102-108);

5 ArgProProArgGlyArg (residues 103-108);

ProProArgGlyArg (residues 104-108).

Since the caries-protecting peptides according to the invention are peptides produced by the human body or  
10 correspond to sequences thereof they are well tolerated. Optimal caries-protecting amounts of these peptides can be easily determined by experiment because the absence of important toxicity restraints. Single doses from 0.1 mg to 1 g will be appropriate for most applications.

15

The invention will be better understood by reference to a drawing and the following description of preferred embodiments thereof.

## 20 DESCRIPTION OF THE DRAWING

Fig. 1 illustrates the native alkaline PAGE patterns of N-terminal acidic peptides from degradation of acidic PRPs (PRP-1 and PRP-3) by strains of  
25 commensal *Streptococcus* and *Actinomyces* species;

Fig. 2 illustrates the gel filtration patterns of fragments formed by degradation of PRP-1 by strains representative for each of the four degradation patterns identified among streptococci and  
30 actinomycetes;

Fig. 3a illustrates the gel filtration patterns of peptide fragments from the degradation of PRP-1 by *S. gordonii* strain SK12 for different time periods;

Fig. 3b illustrates the identification by mass spectrometry of fragments separated using either gel filtration (peaks 1-4, cf. Fig. 3a) or peptide gel filtration (peak 5).

5

#### DESCRIPTION OF PREFERRED EMBODIMENTS

10

EXAMPLE 1. **Isolation of acidic PRPs.** Parotid saliva was collected from three subjects homozygous for PRP-1 and PIF-s using Lashley cups and mild acidic lozenge stimulation. After pooling of the salivas and dilution (1:1 by volume) with 50 mmol/L Tris-HCl, 25 mmol/L NaCl, pH 8.0 (Tris-HCl buffer), the saliva sample was subjected to DEAE-Sephacel column chromatography (15 x 1.6 cm, Pharmacia, Uppsala, Sweden) using a linear gradient of 25 to 1000 mmol/L NaCl in Tris-HCl buffer. The protein fraction containing the acidic PRPs (PRP-1/PIF-s and PRP-3/PIF-f) was concentrated via ultrafiltration using a Centriprep 10 concentrator (Amicon Inc., Beverly, MA), and subjected to gel filtration (HiLoad™ 26/60 Superdex S-200 Prep grade column, Pharmacia) in 20 mmol/L Tris-HCl, 500 mmol/L NaCl, pH 8.0. The resolved protein fractions (PRP-1/PIF-s and PRP-3/PIF-f) were dialyzed against Tris-HCl buffer (Spectra/Pore membrane No. 4, Spectrum Medical Industries, Inc., Houston, TX). Each protein fraction (PRP-1/PIF-s and PRP-3/PIF-f) was finally purified on a Macrorep high Q column (15 x 1.6 cm, Bio-Rad, Hercules, CA) using a linear gradient of 25 to 1000 mmol/L NaCl in 50 mmol/L Tris-HCl, pH 8.0. The purified proteins were extensively dialyzed against water, lyophilized and stored at -20°C.

30

EXAMPLE 2. **Bacterial strains and culturing.** The origins and species designations of strains of *Actinomyces naeslundii*, *Actinomyces odontolyticus*, *A. naeslundii* *genospecies* 1 strain ATCC 12104, *genospecies* 2 strain T14V, *A. odontolyticus* strain PK984 and *A. viscosus* strain 19246 are as previously described (Hallberg K et al, see above; Hallberg K et al., Oral Microbiol Immunol 13 (1989) 188-192; Li et al., 1999, see above). The strains of *S. anginosus*, *S. gordonii*, *S. mitis*, *S. oralis* and *S. sanguis* (provided by Dr. M. Kilian, Department of Oral Biology, Royal Dental College, Aarhus, Denmark) have been described (Kilian et al., 1989; Hsu et al., 1994). *S. mutans* strains Ingbritt, JBP and NCTC 10449, *S. sobrinus* strain SL-1 and *Porphyromonas gingivalis* strains W83 and ATCC 33277 were provided by Dr. J. Carlsson, Department of Oral Biology, Umeå University, Sweden. All strains were grown overnight on Columbia-II-agar base plates (Becton Dickinson and Company, Cockeysville, MD), supplemented with 30 ml of a human erythrocyte suspension per liter, at 37°C in an atmosphere with 5 % CO<sub>2</sub>. Growth of *S. gordonii* strain SK12 identified two morphological types, one forming flat (strain SK12-I) and the other convex (strain SK12-II) colonies. Strain SK12-I (the flat colony-forming type) was selected for the degradation experiments. Neither whole cell soluble protein patterns, as analyzed by SDS-PAGE, nor acidic PRP cleavage patterns distinguished between the two types. The strains intended for degradation experiments were then grown at 37°C for 18 h in 5 mL trypticase soy bean glucose limiting broth (1.7% peptone, 0.3% soy peptone, 0.15% yeast extract, 12.5 mmol/L glucose, 12.5 mmol/L NH<sub>4</sub>HCO<sub>3</sub> in 1 mol/L NaH<sub>2</sub>PO<sub>4</sub>/K<sub>2</sub>HPO<sub>4</sub> buffer, pH 7.3) in an atmosphere with 5% CO<sub>2</sub>. The cells were pelleted by centrifugation at 17,000 x g for 5 min, washed

twice in 0.43% NaCl, 0.042% KCl, 0.1% Na<sub>2</sub>HPO<sub>4</sub>, 0.1% KH<sub>2</sub>PO<sub>4</sub>,  
1% glycerophosphate disodium salt, 0.024% CaCl<sub>2</sub>, and 0.01%  
MgCl<sub>2</sub>.H<sub>2</sub>O (M-DIL buffer), re-suspended in M-DIL buffer at a  
concentration of 2 x 10<sup>9</sup> cells/mL. The bacterial cells (and  
5 cell-free supernatant after pelleting of bacteria by  
centrifugation) were kept on ice prior to degradation  
experiments. The strains intended for adhesion tests were  
metabolically labeled by adding 35S-methionine (200 \*Ci,  
Tran 35S-Label, ICN Pharmaceuticals Inc., Irvine, CA) to  
10 bacteria suspended in 100 µL 10 mmol/L Na<sub>2</sub>HPO<sub>4</sub>, NaH<sub>2</sub>PO<sub>4</sub>,  
0.137 M NaCl, pH 7.2, (PBS) prior to growth on Columbia-II-  
agar plates.

**EXAMPLE 3. Degradation of acidic PRPs.** Equal volumes (200  
15 µL) of purified protein (0.6 mg/mL) and bacteria (2 x 10<sup>9</sup>  
cells/mL), both dissolved in M-DIL buffer, were mixed and  
incubated at 37°C for 15 min, 4 h, 20 h and 1 week. After  
pelleting of the bacteria by centrifugation at 17,000 x g  
for 10 min, the supernatants were aliquoted, lyophilized and  
20 stored at -80°C prior to analysis. In some experiments, cell  
free enzyme supernatants and parotid saliva from defined  
acidic PRP phenotypes were used following the same protocol.  
The saliva was collected as described above and sterilized  
by filtering (0.20 µm Minisart filter, Sartorius, Göttingen,  
25 Germany).

**EXAMPLE 4. Native alkaline PAGE.** Native alkaline  
polyacrylamide gel electrophoresis was performed essentially  
as described (Azen and Yu, 1984). The lyophilized  
30 supernatants were dissolved in 50 µL sample buffer  
containing 1% glycine, 10% glycerol and 0.025% bromophenol  
blue and centrifuged at 17,000 x g for 10 min. The  
electrophoresis was performed using precast Tris-glycine

7.5% resolving gels with 4% stacking gels (Bio-Rad) at 100 V for 20 min followed by 175 V for 1 h 30 min in a buffer containing 0.038 M Tris-glycine, pH 8.4. The gels were stained with 0.1% Coomassie Blue R (Serva Feinbiochemica, Heidelberg, Germany) in 20% trichloroacetic acid (Merck, Darmstadt, Germany) for 16 h, destained in 2% acetic acid for 16 h and finally soaked in water for 2 h.

EXAMPLE 5. **Densitometry.** The degree of acidic PRP degradation was quantified by densitometry of native alkaline PAGE gels using a Model GS-700 Imaging densitometer and the Molecular Analyst Software (Bio-Rad). The degree of degradation of PRP-1 and PRP-3 was scored from 0 to 5 according to the following criteria: 0 = 0<10% , 1 = 10<20%, 2 = 20<40%, 3 = 40<60%, 4 = 60<80%, 5 = 80<100% reduction of PRP-1 or PRP-3 at 4 h of incubation. In the case of certain strains, score 1 denotes the formation after 20 h of incubation of peptide fragments similar to those generated after 4 h by the strains with a high PRP degradation rate (Table 1).

EXAMPLE 6. **Gel filtration.** The lyophilized supernatants obtained by incubation of bacteria with acidic PRPs were dissolved in 200  $\mu$ L 20 mM Tris-HCl, pH 8.0, containing 0.5 M NaCl and subjected to gel filtration on Superose 12 HR 10/30 or a Superdex Peptide HR10/30 (Pharmacia) columns, equilibrated in 20 mM Tris-HCl, pH 8.0. The flow rate was 0.2 mL/min and the absorbance was monitored at 214 nm. Fractions of 1 mL were collected.

EXAMPLE 7. **Hydroxyapatite assay.** Adherence of <sup>35</sup>S-methionine labeled bacteria to acidic PRP-1 was measured by the

hydroxyapatite assay as previously described (Carlén et al., 1998).

EXAMPLE 8. **Mass spectrometry.** All mass spectrometric data  
5 were acquired on a hybrid quadrupole time-of-flight (Q-ToF)  
mass spectrometer (Micromass, Manchester, UK). A Z-  
configured nano spray source was used and samples were  
introduced via gold-coated spraying needles (Protana,  
Odense, Denmark). Detection was all times in the positive  
10 ion mode. Needles were opened manually under a light-  
microscope resulting in an opening of approximately 5  $\mu\text{m}$ .  
Before analysis, remaining contaminants and salt were  
removed by applying the samples to nano-columns; Gel-loader  
tips (Eppendorf, Hamburg, Germany) packed with POROS R3  
15 reverse phase resin (PerSeptive Biosystems, Framingham, MA,  
USA) to a bed volume of approximately 200 nL. Normally, 5  $\mu\text{L}$   
of sample was applied to the resin followed by washing with  
approximately 30  $\mu\text{L}$  0.1% TFA and elution with 60% CH<sub>3</sub>CN in  
1% acetic acid directly into the nano-spray needle.

20

EXAMPLE 9. **N-terminal sequence analysis.** Edman degradation  
was performed directly on proteins blotted (Transblot, Bio-  
Rad) onto PVDF-membranes using an Applied Biosystems 477A  
pulsed liquid phase sequencer (Foster City, CA) with an on-  
25 line PTH 120A analyzer. Sequence analysis was performed with  
cycle programs adapted to the reaction cartridges and  
chemicals from the manufacturer. Yields were calculated from  
sequenced standard  $\kappa$ -lactoglobulin.

30 EXAMPLE 10. **Substrate specificity.** The substrate specificity  
of bacterial strains was measured as previously described  
(Erlanger et al., 1961). Briefly, 25  $\mu\text{L}$  of bacterial  
suspension ( $5 \times 10^9$  cells/mL in M-DIL buffer) was diluted

with 25  $\mu$ L of 0.1 mol/L Tris-HCl, pH 7.0, followed by addition of 50  $\mu$ L of B-Arg-pNA (Sigma, St. Louis, MO) and Z-Gly-Pro-pNA (Bachem, Bulendorf, Switzerland) (8.0 mmol/L in DMSO). After incubation at 37°C for 16 h, the extent of cleavage was measured by the absorbance at 414 nm.

EXAMPLE 11. **Degradation of acidic PRPs by commensal *Streptococcus* and *Actinomyces* species.** Strains of *Streptococcus* and *Actinomyces* species were tested for degradation of acidic PRPs (PRP-1 and PRP-3) by co-incubation of bacteria and protein followed by native alkaline PAGE (Table 1, Fig. 1). Degradation of PRP-1 occurred with *S. oralis* (1 of 4 strains), *S. mitis* (1 of 4 strains), *S. gordonii* (3 of 4 strains), *S. sanguis* (4 of 4 strains), *S. anginosus* (3 of 4 strains) and *A. odontolyticus* (4 of 7 strains), but not with *S. mutans* (3 strains), *S. sobrinus* (1 strain), *A. naeslundii* genospecies 1 (6 strains) and genospecies 2 (7 strains) or *A. viscosus* (1 strain). *S. gordonii* and *A. odontolyticus* displayed high PRP-1 cleavage rates (scores 4 and 5), while other species had moderate (scores 2 and 3) to low (score 1) cleavage rates. While most species showed high PRP-1 relative to PRP-3 cleavage rates, *A. odontolyticus* displayed equal PRP-1 and PRP-3 cleavage rates. Degradation of PRP-1 also occurred in cell-free supernatants (Table 1), and *S. gordonii* strain SK12 (with a high PRP-1 cleavage rate) degraded PRP-1, PRP-2, Db-s, PIF-s and Pa in parotid saliva from defined donors (data not shown).

Both streptococci adhering to and those not adhering to PRP-1 degraded acidic PRPs (Table 1). While *A. naeslundii* genospecies 1 and 2 bound to but did not degrade acidic PRPs, the opposite was true for *A. odontolyticus*. In

addition, both S-IgA1 protease positive and negative strains degraded acidic PRPs (Table 1). Thus, no obvious relationship was found between PRP degradation and adhesion to acidic PRPs or S-IgA1 protease activity.

5

EXAMPLE 12. **Time-dependency of acidic PRP degradation.** The native alkaline PAGE patterns from degradation of acidic PRPs for different times indicated a time-dependency of degradation for all strains (Fig. 1). The time-dependency of degradation of PRP-1 by *S. gordonii* strain SK12 was further  
10 analyzed by gel filtration of fragments formed after different times of incubation (Fig. 3a). Degradation of PRP-1 (peak 1) for 15 min generated a peptide eluting similar to PRP-3 (peak 2) and later-eluting, smaller peptides (peak 3).  
15 Prolonged degradation (20 h) completely converted PRP-1 into the peptide eluting similar to PRP-3 (peak 2) and even later-eluting peptides (peak 4). Even further degradation (1 week) completely transformed all peptides (except for the one eluting similar to PRP-3) into oligopeptides and amino  
20 acids (peak 5), as identified using peptide gel filtration (data not shown).

EXAMPLE 13. **Identity and structural features of acidic PRP-derived peptides.** The peptides generated from PRP-1 by *S. gordonii* strain SK12 were identified by mass spectrometry of  
25 the peptide peaks obtained by gel filtration (Figs 2 and 3). An N-terminal 105 residue peptide Pyr1-Pro104Pro105 (peak 2) and a C-terminal 40 residue peptide Gly111-Pro149Gln150 (peak 3) were identified after initial (15 min) cleavage of  
30 PRP-1 (Fig. 3b). A series of 15-47 residue peptides (peak 4; Pro96-Pro109Gln110, Gly111-Pro130Gln131, Gly111-Pro134Pro135, Gly111-Pro135Gln136, Gly111-Pro140Gln141, Gly111-Pro149Gln150 and Pro104-Pro149Gln150) were identified

after prolonged degradation (20 h). In addition, a  
pyroglutamic acid, Pyr, was found at the N-terminal  
residues of PRP-1 and PRP-3 (Fig. 3b), explaining our  
difficulties in sequencing of N-terminal fragments by Edman  
5 degradation.

EXAMPLE 14. **Patterns of acidic PRP degradation.** The peptide  
profiles displayed by native alkaline PAGE distinguished  
four major degradation patterns, I-IV (Table 1, Fig. 1).  
10 While all four patterns contained N-terminal peptides  
migrating close to PRP-3, the peptide banding patterns were  
unique to a particular strain or species (Fig. 1, Table 1).  
Both species specific (*A. odontolyticus* and *S. gordonii*) and  
multiple patterns within a species (*S. anginosus* and *S.*  
15 *sanguis*), as well as a sharing of patterns between species,  
were observed. In addition, gel filtration of the  
degradation products obtained by a strain representative of  
each pattern verified somewhat deviating profiles,  
containing large (70-75 min retention) and intermediate (80-  
20 95 min retention) peptides (Fig 1b). To investigate the  
substrate specificities associated with acidic PRP  
degradation, strains representative of each degradation  
pattern were tested for truncation of Pro- and Arg-  
containing chromogenic substrates. The strains did not  
25 cleave Z-Gly-Pro-pNA, which is a substrate for prolyl  
endoproteases (Blumberg et al., 1980), or B-Arg-pNA, while  
*P. gingivalis* strain ATCC 33277 cleaved both substrates.

EXAMPLE 15. **Lozenge.** A solution of ArgGlyArgProGln  
30 'acetate' was prepared by dissolving ArgGlyArgProGln in  
water and adding acetic acid to pH 6.5. The aqueous solution  
was freeze-dried and the powder thereby obtained mixed with  
150 g of polyethylene glycol 8000, 150 g of

microcrystalline cellulose, 600 g of mannitol, 10 g of stearic acid are milled to pass a 40 mesh sieve. The mixture is fed to a tablet press to produce 1 g tablets.

5   EXAMPLE 16. **Chewable tablet.** 900 g mannitol and 5 g sodium  
saccharin are screened through a 40-mesh screen and blended  
thoroughly with 40 g ArgGlyArgProGln acetate prepared as  
described above. A binder solution of 20 g of acacia and 50  
g of gelatin in 500 ml water was prepared separately. The  
10   powder was wet granulated using 200 ml of binder solution  
for 1000 powder. After drying overnight at 75°C the granules  
were screened through a 12 mesh screen, mixed with 1 g of  
peppermint oil adsorbed on 3 g of colloidal silica and 25 g  
magnesium stearate. From this mixture 1 g tablets were  
15   compressed to a hardness of 12 kg.

EXAMPLE 17. **Toothpaste.** A suitable toothpaste base for  
incorporating the compounds of the invention is described in  
U.S. Patent No. 3,935,305 (Delaney et al.) which is  
20   incorporated herein by reference; in particular, see Example  
1. A suitable amount of ArgGlyArgProGln acetate (for  
preparation, see above) is 1% by weight of base.

EXAMPLE 18. **Mouthwash.** A suitable mouthwash base for  
25   incorporating the compounds of the invention is described in  
U.S. Patent No. 5,145,664 (Thompson) which is incorporated  
herein by reference; see Example 1. A suitable amount of  
ArgGlyArgProGln acetate (for preparation, see above) is 1%  
by weight of base.

30

LEGENDS TO FIGURES

**Fig 1.** Native alkaline PAGE patterns of N-terminal acidic peptides from degradation of acidic PRPs (PRP-1 and PRP-3) by strains of commensal *Streptococcus* and *Actinomyces* species. Shown are the degradation patterns of strains  
5 representative for each of the four degradation patterns (I-IV) identified among isolates of streptococci and actinomycetes (cf. Table 1). All strains (Table 1) were co-incubated with purified PRP-1 and PRP-3 for different times (15 min, 4h and 20 h) and analyzed for such peptide  
10 patterns.

**Fig. 2.** Gel filtration patterns of fragments formed by degradation of PRP-1 by strains representative for each of the four degradation patterns identified among streptococci  
15 and actinomycetes (cf. Table 1). The strains were incubated with PRP-1 for 15 min and 20 h. The retention times of purified PRP-1 and PRP-3 are indicated by vertical arrows.

**Fig 3a.** Gel filtration patterns of peptide fragments from degradation of PRP-1 by *S. gordonii* strain SK12 for  
20 different times. The numbering of the peaks refer to mass spectrometric identification of the corresponding peptide structures (cf. Fig. 3b). The vertical arrows denote the retention times of purified PRP-1 and PRP-3.

25  
**Fig. 3b.** Identification by mass spectrometry of fragments separated using either gel filtration (peaks 1-4, cf. Fig. 3a) or peptide gel filtration (peak 5). The numbering of peptides by letters A-G denotes the corresponding signals in  
30 the mass spectrum. Pyr indicates a pyroglutamic acid. The mass numbers with an asterisk indicate average masses from de-convoluted mass spectra, while unlabeled mass numbers are consistent with the monoisotopic mass of the peptide.

5

10

15

20 **Table 1. Degradation of acidic PRPs by *Streptococcus* and *Actinomyces* species**

Species <sup>a</sup>	Strain <sup>a</sup>	Acidic PRP degradation <sup>b</sup>			PRP-1 adhesion <sup>d</sup>	IgA1 protease <sup>e</sup>
		PRP-1	PRP-3	Type <sup>c</sup>		
25	<i>S. gordonii</i> SK 12, SK 184	5	1	I	-	-
	SK 120	5	0	I	+	-
	SK 33	0	0	-	-	-
30	<i>S. sanguis</i> SK 85	4	0	I	-	+
	SK 112	2	1	II	+	+
	SK 37	2	1	II	-	+
	SK 162	2	1	III	-	+
35	<i>S. mitis</i> SK 304	1	0	II	-	-
	SK 305	0	0	-	+	-
	SK 96, SK 142	0	0	-	-	-
35	<i>S. anginosus</i> SK 215	3	1	III	-	-
	SK 52	1	1	II	-	-
	SK 63	1	0	II	-	-
	SK 218	0	0	-	-	-

{00538006.1}

	<i>S. oralis</i>	SK 143	1	0	IV	-	+
		SK 2, SK 92	0	0	-	-	+
		C 104	0	0	-	nt	+
5	<i>S. mutans</i>	Ingbritt, JBP	0	0	-	-	nt
		NCTC 10449	0	0	-	nt	nt
	<i>S. sobrinus</i>	SL-1	0	0	-	nt	nt
	<i>A. odontolyticus</i>	T-5-G	5	5	IV	+	nt
		T-1-K	2	1	IV	-	nt
		T-23-N, T-3-G	1 <sup>b</sup>	1	IV	-	nt
10		T-21-N, T-22-N, PK 984	0	0	-	-	nt
	<i>A. naeslundii</i> genospecies 1						
		ATCC 12104, P-3-N, P-5-N,	0	0	-	-	nt
		P-11-N, B-2-G, PK 947					
	<i>A. naeslundii</i> genospecies 2						
15		T14V, P-1-N, P-7-N, P-1-K,	0	0	-	+	nt
		P-1-G, B-7-N, P-2-N					
	<i>A. viscosus</i>	19246	0	0	-	-	nt
	<i>P. gingivalis</i>	W83	5	5	-	-	+

20 a) The sources of the strains are given above.

b) Acidic PRP degradation was carried out by co-incubation of PRP-1 or PRP-3 and bacteria for 15 min, 4 h and 20 h followed by native alkaline PAGE (Fig.1). The degree of cleavage at 4 h was scored from 0 to 5 by densitometry: 0 = 0<10 %, 1 = 10<20 %, 2 = 20<40 %, 3 = 40<60 %, 4 = 60<80 %, and 5 = 80<100 % loss of acidic PRPs. Score 1 labeled with a superscript denotes the formation of degradation products. Cells free supernatant resulted in similar degradation patterns for most strains. 95 % confidence intervals of densitometric runs corresponded to 8 % of mean.

c) The strains were classified into degradation patterns I-IV based on native alkaline PAGE peptide profiles (Fig.1). The type-I pattern displayed a peptide migrating just below PRP-3; The type-II pattern a peptide migrating just below PRP-3 and another between PRP-1 and PRP-3; The type-III pattern two peptides migrating just below and above PRP-3, one between PRP-1 and PRP-3 and a fourth just below PRP-1; and the type-IV pattern a peptide migrating identical to PRP-3 and another between PRP-1 and PRP-3 although closer to PRP-1 compared to patterns II and III.

d) Adhesion of  $^{35}\text{S}$ -labeled bacteria to PRP-1-coated hydroxyapatite beads. Adhesion exceeding 15 % of added cells was considered positive. Adhesion of *Actinomyces* was tested at 5  $\mu\text{g/ml}$  of PRP-1 and for other bacteria at 30  $\mu\text{g/ml}$  of PRP-1. The criteria for positive binding and assay conditions differ from those in other studies of adhesion of streptococci and *P. gingivalis* (Hsu et al., 1994).

e) S-IgA protease activity of commensal streptococci (Kilian et al., 1989), *P. gingivalis* (Kilian, 1981) and *Actinomyces* species, which lack S-IgA1 protease activity (M. Kilian, personal communication).

**Table 2. Simplified map of generated peptides in comparison with PRP-1.**

Peak	Peptide	Mass (Da)
1	Pyr1----Pro149-Gln150	15 514.0*
2	Pyr1----Pro104-Pro105	11 005.5*
3	Gly111---Pro149-Gln150	3 930.0
40	4 Pro96----Pro109-Gln110 (A)	1 663.7
	4 Gly111---Pro130-Gln131 (B)	2 082.1
	4 Gly111---Pro134-Pro135 (C)	2 430.4
	4 Gly111---Pro135-Gln136 (D)	2 558.4
	4 Gly111---Pro140-Gln141 (E)	3 053.6
45	4 Gly111---Pro149-Gln150 (F)	3 930.0

{00538006.1}

4 Pro104---Pro149-Gln150 (G) 4 718.3  
5 Oligopeptides/amino acids

---

5 The potential cleavage sites at peptide bonds formed at Pro or  
Gln residues are given. The presumed Arg-containing pentapeptide  
is blown up, ProGln-termini are marked by black circles and the  
post-translational cyclization of the N-terminal Glu residue to a  
pyroglutamic acid residue is marked Pyr. The verification by mass  
10 spectrometry of phosphorylation of Ser at positions 8 and 22 is  
marked.

## C l a i m s

1. An oligopeptide protecting against dental caries  
5 comprising two arginine residues selected from the group  
consisting of pentapeptide, hexapeptide, heptapeptide,  
octapeptide, nonapeptide and decapeptide.
2. The oligopeptide of claim 1 comprised by the sequence  
10 GlyGlyHisProArgProProArgGlyArgProGlnGlyProProGlnGln.
3. The oligopeptide of claim 2 ArgGlyArgProGln.
4. The oligopeptide of claim 2 selected from:  
15 ArgGlyArgProGln;  
ArgGlyArgProGlnGly;  
ArgGlyArgProGlnGlyPro;  
ArgGlyArgProGlnGlyProPro;  
ArgGlyArgProGlnGlyProProGln;  
20 ArgGlyArgProGlnGlyProProGlnGln;  
GlyGlyHisProArgProProArgGlyArg;  
GlyHisProArgProProArgGlyArg;  
HisProArgProProArgGlyArg;  
ProArgProProArgGlyArg;  
25 ArgProProArgGlyArg;  
ProProArgGlyArg.
5. A method of preventing dental caries comprising the oral  
administration of a prevention-effective amount of the  
30 peptide of any of claims 1-4.
6. A composition for preventing dental caries comprising a  
prevention-effective amount of the oligopeptide of any of  
claims 1-4 and a suitable carrier.

7. The composition of claim 6 wherein the carrier is selected from the group consisting of toothpaste, mouthwash chewing-gum, lozenge, chewable tablet.

5

8. The manufacture of a medicament for prevention of dental caries comprising a prevention-effective amount of the oligopeptide of any of claims 1-4.

## A b s t r a c t

A penta- to decapeptide containing two or more Arg  
protecting against dental caries is comprised by the amino  
5 acid sequence

GlyGlyHisProArgProProArgGlyArgProGlnGlyProProGlnGln.

Also disclosed is a composition for preventing dental caries  
comprising an effective amount of the peptide, and a  
corresponding method of use.




Fig. 1




Fig. 2




Fig. 3a






Fig. 3b

UNITED STATES OF AMERICA COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION			FILE NO. C2432.0044
<p>As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named) of the subject matter which is claimed and for which a patent is sought on the invention entitled:</p> <p><b>PREVENTION OF DENTAL CARIES</b></p>			
<p>the specification of which is attached hereto, unless the following box is checked:</p> <p><input checked="" type="checkbox"/> was filed on <u>November 16, 2001</u> as United States patent Application Number or PCT International patent application number <u>10/009,709</u> and was amended on <u>November 16, 2001</u>.</p>			
<p>I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.</p> <p>I acknowledge the duty to disclose all information known to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.</p> <p>I hereby claim priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate or United States provisional application(s) listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:</p>			
Prior Foreign or Provisional Application(s)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. § 119
Sweden	9901773-3	May 17, 1999	YES <u>X</u> NO
PCT	PCT/SE00/00930	May 11, 2000	YES <u>X</u> NO
			YES NO
<p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.</p>			
UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)	
<p>I hereby appoint customer no. 32172 DICKSTEIN, SHAPIRO, MORIN &amp; OSHINSKY, LLP, and the members of the firm, Edward A. Meilman, Reg. No. 24,735, Gary M. Hoffman, Reg. No. 26,411, Steven I. Weisburd, Reg. No. 27,409, Thomas J. D'Amico, Reg. No. 28,371, Donald A. Gregory, Reg. No. 28,954, Stephen A. Soffen, Reg. No. 31,063, James W. Brady, Jr., Reg. No. 32,115, Jon D. Grossman, Reg. No. 32,699, Mark J. Thronson, Reg. No. 33,082, Michael J. Scheer, Reg. No. 34,425, and Eric Oliver, Reg. No. 35,307, as attorneys with full power of substitution and revocation to prosecute this application, to transact all business in the Patent &amp; Trademark Office connected therewith and to receive all correspondence.</p>			
<p>SEND CORRESPONDENCE TO: DICKSTEIN, SHAPIRO, MORIN &amp; OSHINSKY, LLP 1177 Avenue of the Americas, 41st Floor New York, NY 10036-2714</p>		<p>DIRECT TELEPHONE CALLS TO: (212) 835-1400</p>	
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p>			
<p>FULL NAME OF SOLE OR FIRST INVENTOR <u>Nicklas STROMBERG</u></p>		<p>INVENTOR'S SIGNATURE </p>	<p>DATE <u>2002-05-25</u></p>
<p>RESIDENCE (City and either State or Foreign Country) <u>S-903 37 Umea, Sweden</u></p>		<p>COUNTRY OF CITIZENSHIP <u>Sweden</u> <u>SEX</u></p>	
<p>POST OFFICE ADDRESS <u>Ragangen, 6A, S-903 37 Umea, Sweden</u></p>			
<p>FULL NAME OF SECOND JOINT INVENTOR (IF ANY) <u>Ingegerd JOHANSSON</u></p>		<p>INVENTOR'S SIGNATURE </p>	<p>DATE <u>2002-05-25</u></p>
<p>RESIDENCE (City and either State or Foreign Country) <u>S-903 39 Umea, Sweden</u></p>		<p>COUNTRY OF CITIZENSHIP <u>Sweden</u> <u>SEX</u></p>	
<p>POST OFFICE ADDRESS <u>Svampvaagen 18, S-903 39 Umea, Sweden</u></p>			

SEQUENCE LISTING

<110> Stromberg, Nicklas  
Ingegerd, Johansson

<120> PREVENTION OF DENTAL CARIES

<130> P/2432-44

<140> Not Yet Known

<141> 2001-11-16

<150> PCT/SE00/00930

<151> 1999-05-17

<160> 13

<170> PatentIn Ver. 2.0

<210> 1

<211> 5

<212> PRT

<213> Homo sapiens

<400> 1

Arg Gly Arg Pro Gln

1 5

<210> 2

<211> 6

<212> PRT

<213> Homo sapiens

<400> 2

Arg Gly Arg Pro Gln Gly

1 5

<210> 3

<211> 7

<212> PRT

<213> Homo sapiens

<400> 3

Arg Gly Arg Pro Gln Gly Pro

1 5

<210> 4  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Arg Gly Arg Pro Gln Gly Pro Pro  
 1 5

<210> 5  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 5  
 Arg Gly Arg Pro Gln Gly Pro Pro Gln  
 1 5

<210> 6  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 6  
 Arg Gly Arg Pro Gln Gly Pro Pro Gln Gln  
 1 5 10

<210> 7  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 7  
 Gly Gly His Pro Arg Pro Pro Arg Gly Arg  
 1 5 10

<210> 8  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 8  
 Gly His Pro Arg Pro Pro Arg Gly Arg

1 5

<210> 9  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 9  
His Pro Arg Pro Pro Arg Gly Arg  
1 5

<210> 10  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 10  
Pro Arg Pro Pro Arg Gly Arg  
1 5

<210> 11  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 11  
Arg Pro Pro Arg Gly Arg  
1 5

<210> 12  
<211> 5  
<212> PRT  
<213> Homo sapiens

<400> 12  
Pro Pro Arg Gly Arg  
1 5

<210> 13  
<211> 17  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 13

Gly Gly His Pro Arg Pro Pro Arg Gly Arg Pro Gln Gly Pro Pro Gln  
1 5 10 15

Gln